<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129372">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01816776</url>
  </required_header>
  <id_info>
    <org_study_id>Respicardia CR-1005</org_study_id>
    <nct_id>NCT01816776</nct_id>
  </id_info>
  <brief_title>Respicardia, Inc. Pivotal Trial of the remedÄ“ System</brief_title>
  <official_title>A Randomized Trial Evaluating the Safety and Effectiveness of the Remede System in Patients With Central Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Respicardia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Respicardia, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this prospective, multicenter, randomized trial is to evaluate the
      safety and effectiveness of therapy delivered by the remede system in subjects with moderate
      to severe central sleep apnea and optimal medical management, compared to outcomes in
      randomized control subjects receiving optimal medical management and implanted but inactive
      remede systems.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Apnea-hypopnea index (AHI)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary effectiveness objective of the trial is to demonstrate that the Treatment group achieves an AHI reduction from baseline to 6 months post therapy initiation that is greater than the Control group.  The primary effectiveness endpoint will be evaluated by comparing the proportions of subjects in the two study groups that meet the following success criterion:  Subject success on the primary AHI endpoint is defined as a subject achieving a 50% or greater reduction in AHI from baseline to 6 months post-therapy initiation visit.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">173</enrollment>
  <condition>Sleep Apnea, Central</condition>
  <condition>Sleep Disordered Breathing</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects implanted with the remede system device and randomized to the Treatment group will receive optimal medical therapy and have the remede system initiated to deliver phrenic nerve stimulation at the Therapy Initiation Visit (1 month post device implant).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects implanted with the remede system device and randomized to the Control group will receive optimal medical therapy through the 6-month Post-Therapy Initiation Visit.  Control group subjects will have the remede system initiated to deliver phrenic nerve stimulation at the 6-month Post-Therapy Initiation Visit (7 months post device implant).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment Group (remede; phrenic nerve stimulation)</intervention_name>
    <description>device implant, optimal medical therapy and device initiation 1 month post implant.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>remede System</other_name>
    <other_name>Phrenic Nerve Stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control Group (Optimal Medical Therapy)</intervention_name>
    <description>device implant, optimal medical therapy and delayed device initiation (7 months post device implant)</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Optimal Medical Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years of age

          2. Central Sleep apnea confirmed by core lab analysis of PSG with EEG within 40 days of
             scheduled implant:

               -  Apnea/Hypopnea Index (AHI) greater than or equal to 20;

               -  Central Apnea Index (CAI) at least 50% of all apneas, with at least 30 central
                  apnea events;

               -  Oxygen Desaturation Index (OAI) less than or equal to 20% of the total AHI

          3. Medically stable for 30 days prior to all baseline testing (including PSG), i.e., no
             hospitalizations for illness, no breathing mask-based therapy, and on stable
             medications and therapies:

               -  Stable medications are defined as no changes during this period except for those
                  within a pre-specified sliding scale medication regimen;

               -  If the subject has heart failure, the baseline testing (including PSG) should
                  occur at least 6 months after initial diagnosis;

               -  If the subject has systolic heart failure, the baseline testing (including PSG)
                  should occur after maximally titrating beta blockers, ACE-I and other
                  medications indicated in the current guidelines (unless contraindicated or not
                  considered medically necessary) and after receiving any indicated device therapy
                  including devices for cardiac resynchronization therapy and/or primary
                  prevention of sudden cardiac death;

               -  If subject has a hospitalization or physician visit requiring IV medication
                  between the screening PSG and implant, the subject must be re-screened when
                  stable

          4. Expected to tolerate study procedures in the opinion of the investigator, in
             particular:

               -  Ability to lie down long enough to insert the remede system without shortness of
                  breath and able to tolerate instrumentation for the Polysomnogram/Polygram
                  testing;

               -  Expected to tolerate therapy titration and the sensation of therapy, and
                  communicate therapy experience.

          5. In the investigator's opinion, willing and able to comply with all study requirements

          6. Signed the Institutional Revew Board/Medical Ethics Committee approved informed
             consent (HIPAA authorization in the U.S.)

        Exclusion Criteria:

          1. Pacemaker dependent subjects without any physiologic escape rhythm

          2. Suspected inability to place catheter for delivery of stimulation lead (e.g.
             previously know coagulopathy, distorted anatomy, prior failed pectoral implant, etc.)

          3. Evidence of phrenic nerve palsy

          4. More than 2 previous open chest surgical procedures (e.g., CABG)

          5. Etiology of central sleep apnea known to be caused primarily by pain medication

          6. Documented history of psychosis or severe bipolar disorder

          7. Cerebrovascular accident (CVA) within 12 months of baseline testing

          8. History of idiopathic pulmonary hypertension, World Health Organization Class 1

          9. Limited pulmonary function with either FEV1/FVC less than 65% of predicted value or
             FVC less than 60% of predicted value

         10. Baseline oxygen saturation less than 92% while awake and on room air after 5 minutes
             of quiet rest

         11. Anticipated need for chronic oxygen therapy or breathing mask-based therapy for 6
             months post therapy initiation visit

         12. Active infection or sepsis within 30 days of enrollment

         13. Currently on renal dialysis or creatinine level greater than 2.5 mg/dL or calculated
             creatinine clearance equal to or less than 30 ml/min using the Cockcroft-Gault
             equation

         14. Poor liver function with baseline aspartate transaminase (AST), alanine transaminase
             (ALT), and/or total bilirubin greater than 3 times the upper limit of normal (per lab
             normals at each site)

         15. Hemoglobin less than 8 gm/dL

         16. In subjects with heart failure, ACC/AHA Heart Stage D

         17. Within the 3 months prior to baseline testing, any of the following: uncorrected
             severe valvular stenosis, valve replacement or repair (percutaneous or surgical),
             myocardial infarction (MI), coronary artery bypass grafting (CABG) surgery,
             percutaneous coronary intervention (PCI), cardiac ablation, new cardiac
             resynchronization device or new pacemaker implant

         18. New implantable cardioverter defibrillator or any implantable device generator
             change-out within 30 days prior to baseline testing or anticipated within the first 6
             months of enrollment

         19. Other anticipated surgery or invasive procedure expected to affect ability to perform
             testing at 6-month post-therapy initiation visit

         20. Unstable angina

         21. Allergy to or intolerant of contrast dye

         22. Pregnancy or of child bearing potential without a negative pregnancy test within 10
             days prior to remede system implant

         23. Life expectancy or expected time to transplant or left ventricular assist device of
             less than 12 months

         24. Currently enrolled or planning to enroll in another study that may conflict with
             protocol requirements or confound subject results in this trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Rosa Costanzo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midwest Heart Specialists</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robin Germany, MD</last_name>
    <email>rgermany@respicardia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene Rivers</last_name>
      <email>brenda.rivers@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Adkins, RN</last_name>
      <email>maria.adkins@jax.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas B. Chapman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Medical Group</name>
      <address>
        <city>Downer's Grove</city>
        <state>Illinois</state>
        <zip>60566</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Szydlowska</last_name>
    </contact>
    <investigator>
      <last_name>Ali Valika, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edward Hospital-Advocate Medical Group</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60566</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Heidenreich, RN</last_name>
      <email>debra.heidenreich@advocatehealth.com</email>
    </contact>
    <investigator>
      <last_name>Moeen Saleem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Marshall, RN, MS</last_name>
      <email>jmarshal@medicine.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Gottlieb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne Wingo, RN</last_name>
      <email>jwingo@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Berger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zora Injic</last_name>
      <email>zcvetko1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Mauricio Velez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Detroit Clinical Research Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candice Shallal</last_name>
    </contact>
    <investigator>
      <last_name>Salwan Anton, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Dickinson, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Nancy Dekoff</last_name>
      <email>Nancy.Dekoff@spectrumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Dickinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>United Heart and Vascular (Allina)</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Thomas</last_name>
      <email>kari.thomas@allina.com</email>
    </contact>
    <investigator>
      <last_name>Alan Bank, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Haffey</last_name>
      <email>khaffey@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Kao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Platts</last_name>
      <email>aplatts@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Joseph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bryan Heart</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Lassen, RN</last_name>
      <email>teresa.lassen@bryanheart.com</email>
    </contact>
    <investigator>
      <last_name>Steven Krueger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cooper Health System</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Logan, LPN</last_name>
      <email>logan-amanda@cooperhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Fredrick Ginsberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Medical Group, Inc. Presbyterian Sleep Health Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlyn Sander</last_name>
      <email>cjsander@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth D. Weeks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center - Novant</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stan Andrews, MS</last_name>
      <email>scandrews@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Drucker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Lindner Center for Research and Education at Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vickie Frey, RN</last_name>
      <email>victoria.frey@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Beyerbach, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Bouscher</last_name>
      <email>bouschp@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Wilson Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Sow</last_name>
      <email>Angela.sow@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Ayesha Hasan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lou Anne Kruse, RN</last_name>
      <email>LAKruse@lghealth.org</email>
    </contact>
    <investigator>
      <last_name>Roy S. Small, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciera Damon</last_name>
      <email>ciera.damon@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Lee Goldberg, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stern Cardiovascular</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Hamilton</last_name>
    </contact>
    <investigator>
      <last_name>Frank McGrew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Carreon, RN</last_name>
      <email>gloria.carreon@mhshealth.com</email>
    </contact>
    <investigator>
      <last_name>Chandra Kunavarapu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Hall, RN, BSN</last_name>
      <email>khall@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Keyur Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Mancl</last_name>
      <email>mancl.kathleen@mcrf.mfldclin.edu</email>
    </contact>
    <investigator>
      <last_name>Jaime Boero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bad Oeynhausen- Heart &amp; Diabetes Center</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgit Krause</last_name>
      <email>BKrause@hdz-nrw.de</email>
    </contact>
    <investigator>
      <last_name>Olaf Oldenburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bad Rothenfelde-Schuchtermannklinic</name>
      <address>
        <city>Bad Rothenfelde</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Grove, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ranier Grove, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite Medical School, Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan von Haehling, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stephan von Haehling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bernau-Herzzentruym Brandenburg</name>
      <address>
        <city>Bernau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Butter, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Butter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bielefeld-Klinikun</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Stellbrink, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christoph Stellbrink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamburg: Universitares Herzzentrum</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Aydin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ali Aydin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Bitter, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Bitter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ambulantes Herzzentrum-Kassel</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Arnold, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fourth Military Hospital</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Kolodziej, MD</last_name>
    </contact>
    <investigator>
      <last_name>Piotr Ponikowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 21, 2014</lastchanged_date>
  <firstreceived_date>March 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Central</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
